On 26 January 2026, GR Life Style Company Limited (Stock Code: 108) entered into a non-binding Strategic Cooperation Memorandum with Mingzhi Medical Technology (Shanghai) Co., Ltd. According to the announcement, both parties aim to integrate core resources and leverage AI technology to deepen collaboration in oncology real-world research and innovative research and development of traditional Chinese medicine.

The agreement outlines plans to jointly promote digital healthcare initiatives, including building an end-to-end digital marketing and health management system for pharmaceutical companies and establishing a digital clinical trial collaboration platform. GR Life Style Company Limited also intends to utilize its capital market advantages and brand influence to support Mingzhi Medical’s projects and market expansion.

Mingzhi Medical is a limited liability company in the People’s Republic of China specialized in digital healthcare services. Its oncology-focused specialty database covers more than 5,000 experts and approximately 300,000 oncology patients, backed by proprietary high-precision algorithms and breakthroughs in technologies related to traditional Chinese medicine. The company has undertaken multiple national and provincial-level scientific research projects, forming a robust industrial data chain that spans core hospitals, pharmaceutical companies, industry associations, technology companies, and universities.

According to the announcement, further details on the specific business cooperation model will be negotiated and confirmed in a formal agreement. As the memorandum is non-binding, the transactions outlined may or may not proceed. The announcement advises cautious consideration when interpreting these potential developments and notes that GR Life Style Company Limited will issue further updates when appropriate.